BioCentury
ARTICLE | Company News

Active Biotech, NeoTX Therapeutics deal

October 31, 2016 7:00 AM UTC

Active granted NeoTX exclusive, worldwide rights to develop and commercialize Anyara naptumomab estafenatox for cancer. Active will receive a $250,000 upfront payment and is eligible for development, ...